QUOTE AND NEWS
TheStreet.com  Aug 27  Comment 
Updated with more information below.BOSTON (TheStreet) -- The two leading drugs to treat Duchenne muscular dystrophy, drisapersen and eteplirsen, are accepted officially for priority review by the U.S. Food and Drug Administration. With the...
Motley Fool  Aug 27  Comment 
Sarepta Therapeutics and BioMarin now have drugs under FDA review.
Market Intelligence Center  Aug 27  Comment 
BioMarin Pharmaceutical (BMRN) traded between $120.09 and $128.26 before closing at $128.10 Wednesday and presents some attractive trading opportunities today according to MarketIntelligenceCenter.com's patented algorithms. The computer program...
FierceBiotech  Aug 26  Comment 
The FDA has awarded priority review status to Sarepta Therapeutics' eteplirsen. The regulatory go sign means Sarepta is still tucked in just behind BioMarin in the race to bring a therapy for Duchenne muscular dystrophy to market, with analysts...
Benzinga  Aug 24  Comment 
Medivation, Inc. (NASDAQ: MDVN) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that they have entered into an asset purchase agreement under which Medivation will acquire all worldwide rights to talazoparib (formerly referred to...
Motley Fool  Aug 22  Comment 
BioMarin's drisaperson for DMD has just landed an FDA designation that could net the company a voucher worth hundreds of millions of dollars.
Benzinga  Aug 21  Comment 
In a report published Friday, UBS analyst Andrew Peters maintained a Buy rating on BioMarin Pharmaceutical Inc (NASDAQ: BMRN), with a price target of $155, after survey data revealed high optionality on BMN270. Peters said that an analysis of...
FierceBiotech  Aug 21  Comment 
Rivals Sarepta Therapeutics and BioMarin ​Pharmaceutical are in line to become the next recipients of an FDA coupon for a fast review, each potentially picking up a sellable asset that recently brought in $350 million on the open market.
newratings.com  Aug 20  Comment 
JERUSALEM (dpa-AFX) - BioMarin Pharmaceutical Inc.'s (BMRN) drug candidate Drisapersen, a potential treatment for patients with Duchenne Muscular Dystrophy who are amenable to exon 51 skipping treatment, has been granted a rare pediatric...
Benzinga  Aug 19  Comment 
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for drisapersen, a potential treatment for patients with Duchenne Muscular Dystrophy (DMD)...




 

BioMarin Pharmaceutical Inc. (BMRN), a developer of enzyme-related therapies (ERT), co-markets Aldurazyme with Genzyme Corporation (GENZ) for the treatment of MPS-I (mucopolysaccharidosis). MPS-I is a rare genetic enzyme deficiency disorder, afflicting roughly 3,000 people worldwide, caused by the lack of a specific enzyme involved in lysosomal storage. More common names for mucopolysaccharidosis are Hurler's Syndrome, Hurler-Scheie, and Scheie's Disease. The company's other developed product, Naglazyme, for MPS-VI, recently entered the market. MPS-VI is also a rare genetic enzyme deficiency disorder, with an estimated 1,100 people suffering from it worldwide. The company's third lead drug, Kuvan, received FDA approval for the treatment of PKU in December 2007. With the recent launch of Kuvan, the company now has three products on the market. The company also receives royalties and license revenue on sales of the Orapred franchise from Alliant Pharmaceuticals. In 2004, the company acquired Orapred, a grape-flavored oral corticosteroid liquid for the treatment of severe asthma in children and subsequently licensed the franchise to Alliant Pharmaceuticals in March 2006. BioMarin, headquartered in Novato, CA, employs roughly 300 people.

Business Overview

Business & Financial Metrics

In 2009, BMRN incurred a net loss of $488 thousand on revenues of $324.7 million. This represents a real turnaround from 2008, when the company earned $30.8 million on $296.5 million in revenues.[1]

Geographical Distribution[2]

BioMarin generates the majority of its revenues from sales in Europe.

IMAGE:BMRN-Geography2009.jpg[2]

Competition

BioMarin competes with companies like:

References

  1. BMRN 2009 10-K pg. 36  
  2. 2.0 2.1 BMRN 2009 10-K pg. 16  
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki